Abstract:Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising therapeutic target for treating various cancers (such as breast cancer, liver cancer, etc.) and other diseases (blood diseases, cardiovascular diseases, etc.), owing to its observed overexpression, thereby presenting significant opportunities in drug development. Since its discovery in 2004, extensive research has been conducted on LSD1 inhibitors, with notable contributions from computational approaches. This review systematically summarizes LSD1 inhibitors investigated through computer-aided drug design (CADD) technologies since 2010, showcasing a diverse range of chemical scaffolds, including phenelzine derivatives, tranylcypromine (abbreviated as TCP or 2-PCPA) derivatives, nitrogen-containing heterocyclic (pyridine, pyrimidine, azole, thieno[3,2-b]pyrrole, indole, quinoline and benzoxazole) derivatives, natural products (including sanguinarine, phenolic compounds and resveratrol derivatives, flavonoids and other natural products) and others (including thiourea compounds, Fenoldopam and Raloxifene, (4-cyanophenyl)glycine derivatives, propargylamine and benzohydrazide derivatives and inhibitors discovered through AI techniques). Computational techniques, such as virtual screening, molecular docking and 3D-QSAR models, have played a pivotal role in elucidating the interactions between these inhibitors and LSD1. Moreover, the integration of cutting-edge technologies such as artificial intelligence holds promise in facilitating the discovery of novel LSD1 inhibitors. The comprehensive insights presented in this review aim to provide valuable information for advancing further research on LSD1 inhibitors.

LSD1 inhibitors for anticancer therapy: a patent review (2017-present)

Therapeutic potential of targeting LSD1/ KDM1A in cancers

LSD1 inhibitors for cancer treatment: Focus on multi-target agents and compounds in clinical trials

Targeting LSD1 in cancer: Molecular elucidation and recent advances

Pharmacological Inhibition of LSD1 for Cancer Treatment

Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies

Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks

Annual review of LSD1/KDM1A inhibitors in 2020

LSD1/KDM1A Inhibitors in Clinical Trials: Advances and Prospects

Recent advances in inhibitors of lysine specific demethylase 1 in tumor therapies

Targeting LSD1 in tumor immunotherapy: rationale, challenges and potential

Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy

Medicinal Chemistry Insights in the Discovery of Novel LSD1 Inhibitors

Targeting LSD1 for acute myeloid leukemia (AML) treatment

Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia: Clinical Significance and Progress to Date

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Lysine-specific Histone Demethylase 1 (LSD1): A Potential Molecular Target for Tumor Therapy

LSD1: an Emerging Face in Altering the Tumor Microenvironment and Enhancing Immune Checkpoint Therapy

Utilizing a structure-based virtual screening approach to discover potential LSD1 inhibitors

Anticancer Drugs of Lysine Specific Histone Demethylase-1 (LSD1) Display Variable Inhibition on Nucleosome Substrates

LSD1 is a promising target to treat cancers by modulating cell stemness